Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

JENBURKT PHARMACEUTICALS LTD.

NSE : NABSE : 524731ISIN CODE : INE354A01013Industry : Pharmaceuticals & DrugsHouse : Private

BSE1306.50-14.7 (-1.11 %)

PREV CLOSE ( ) 1321.20

OPEN PRICE ( ) 1324.80

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 711

TODAY'S LOW / HIGH ( )1298.20 1334.00

52 WK LOW / HIGH ( ) 815.81410

NSE

This Company is not listed in NSE

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1985

Management Info

Ashish U Bhuta - Chairman Ashish U Bhuta - Managing Director

Registered Office

Address Nirmala Apartments,93 Jayprakash Road,Andheri (West),
Mumbai,
Maharashtra-400058

Phone 022-67603603

Email investor@jenburkt.com / info@jenburkt.com

Website www.jenburkt.com

Registrars Details

Bigshare Services Pvt Ltd

Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai

Listing : BSE

NEWS

23Jun Jenburkt Pharmaceuticals informs about
With reference to letter no. JPL/CS/2206/2024 dated 20th June, 2025, Jen..

24Mar Jenburkt Pharmaceuticals informs about
Jenburkt Pharmaceuticals has informed that the trading window for all th..

29Jan Jenburkt Pharmaceuticals informs about
With reference to letter No. JPL/CS/2154/2025 dated 28th January, 2025,..

21Jan Jenburkt Pharmaceuticals informs about
In terms of Regulation 30 read with Schedule II Para A of the Securities..

06Nov Jenburkt Pharmaceuticals informs about
With reference to letter No. JPL/CS/2140/2024 dated 5th November, 2024,..

Financials

Rs. in Millions

	QTR Mar 25	ANNUAL 25
Net Profit	85.36	320.6
Gross Profit	118.35	439.32
Operating Profit	127.37	471.13
Net Sales	410.47	1516.92

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE) 34192.50 (0.40%)	M.Cap ( in Cr)72656.68
Emcure Pharma (BSE) 1425.40 (5.00%)	M.Cap ( in Cr)27012.52
Sanofi Cons. Health (BSE) 5112.20 (1.27%)	M.Cap ( in Cr)11773.71
Bharat Parenterals (BSE) 1603.75 (3.47%)	M.Cap ( in Cr)1105.30
BDH Inds (BSE) 349.80 (17.21%)	M.Cap ( in Cr)201.39

Shareholding Pattern

	NON-INSTITUTION	53.22%
	PROMOTERS	46.67%
	MUTUAL FUNDS/UTI	0%
	FI/BANKS/INSURANCE	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
No Data Found

Risk Disclosures on Derivatives

Smart Quotes

JENBURKT PHARMACEUTICALS LTD.